Skip to main content
Premium Trial:

Request an Annual Quote

Tripos s Revenues Slide 16 Percent, Earnings Increase in Q2

NEW YORK, July 28 (GenomeWeb News) - Tripos yesterday reported a drop in revenues amidst increased earnings for the second quarter of 2005.


Tripos' revenues were $13.4 million, down 16 percent from last year's $15.9 million during the same period. This decrease was "primarily due to the anticipated decline for the current stage of our Pfizer chemical file enrichment contract," said president and CEO John McAlister in a statement.


Research and development costs fell to $2 million, down from $2.5 million during the year-ago period.


Net income for the quarter was $1.7 million, or $.17 per share, up from $156,000, or $.02 per share, during last year's second quarter. Most of these earnings came from an income tax benefit of nearly $2 million.


As of June 30, Tripos had $6.2 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more